Proteinuria Therapeutics Market Detailed In New Research and Booming Growth by 2028 | GlaxoSmithKline, Chinook Therapeutics, Novartis International AG, AbbVie

Proteinuria is a condition that occurs when the proteins in your body are not able to be absorbed by the bloodstream. Because proteins are the building blocks of all life, the absence of these essential amino acids can result in malfunctioning and even death.

Proteinuria can be attributed to various causes such as: kidney disease, kidney infection and malignancy, thyroid disease, myeloid leukemia, diabetes, anemia, and hyperchloremic metabolic acidosis, among others. Proteinuria can also be hereditary or a result of increased consumption of protein rich foods. Other people can experience proteinuria by drinking milk or by ingesting animal products such as eggs. The most common cause of proteinuria though is the decreased activity of the kidney.

Get Sample PDF with Impact of COVID19:

Signs and symptoms of proteinuria due to kidney problems are relatively common. They include frequent thirst, dry mouth, frequent urination, painful urination, and frequent urination, particularly after eating or after the consumption of carbohydrates. It can be diagnosed and detected by using test such as 24 hour urine test, glomerular filtrate rate (GMR) blood test, ultrasound or computed tomography (CT) scan, and kidney biopsy.

The treatment is determined by the underlying condition that caused the proteinuria. Each condition requires different treatment plans. For example, if kidney disease is diagnosed, a treatment plan may consist of medication such as diuretics, dietary changes, weight loss, and exercise. Patients with diabetes and hypertension who have proteinuria may require blood pressure medication such as angiotensin-converting enzyme (ACE) inhibitors, and those with diabetes might need to control their blood sugar level.

The growing prevalence of chronic kidney disease is driving growth of the global proteinuria therapeutics market as CDK is a major cause of proteinuria is expected to drive growth of the global proteinuria therapeutics market. For example, according to the Centers for Disease Control and Prevention, in March 2021, over one in seven, accounting for 37 million people (15% of the adults), are estimated to have chronic kidney disease in the U.S. Moreover, according to the same source, Chronic kidney disease was found to be more prevalent in people aged 65 years or older (38%) compared to people aged 45–64 years (12%) or 18-44 years (6%).

Rise in clinical trial for development of drugs for the treatment of chronic kidney disease and proteinuria is again projected to augment global proteinuria therapeutics market growth. For instance, on June 06, 2021, Novartis, a global healthcare company, revealed their Phase II primary endpoint data demonstrating that investigational ‘iptacopan’ reduced protein in the urine (proteinuria), a key risk predictor associated  with progression of kidney failure. Iptocan is a first-in-class, oral, targeted factor B inhibitor, which also showed a stabilizing kidney function in patients with IgA nephropathy.

Get Extensive Analysis of COVID-19 Impact on Proteinuria Therapeutics Market @

Key players are adopting business strategies such as mergers, agreements, and acquisitions which is further expected to propel growth of the global proteinuria therapeutics market over the forecast period. For instance, on January 10, 2020, Chinook Therapeutics Inc., a biotechnology firm focused on developing precision medicines for kidney diseases, announced a license agreement with AbbVie, a research-based global biopharmaceutical company, for worldwide exclusive rights to ‘atrasentan’, an endothelin receptor antagonist. Atrasentan is being developed for the treatment of primary glomerular diseases, which are characterized by proteinuria.

Geographically, North America is expected to account for the largest share in global proteinuria therapeutics market over the forecast period, owing to the submission of new drug applications for the treatment of proteinuria associated diseases such as nephropathy. For instance, on March 15, 2021, Calliditas Therapeutics AB officially confirmed the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Nefecon, a novel oral formulation targeting IgA1 down regulation for the treatment of primary IgA Nephropathy (IgAN). Nefecon in the part A of phase III study met its primary endpoint of lowering proteinuria compared to placebo, as well as stabilizing estimated glomerular filtration rate (eGFR) at nine months. Calliditas Therapeutics is a specialty pharmaceutical company, which focuses on developing novel treatments for orphan indications, with an initial focus on renal and hepatic diseases.

Moreover, increasing drug approvals by regulatory authorities for the treatment of proteinuria associated diseases such as lupus nephritis, Europe is expected to witness a lucrative growth in global proteinuria therapeutics market over the forecast period. For example, on May 05, 2021, GlaxoSmithKline plc. (GSK), a science-led global healthcare company announced that the European Commission approved the expanded use of intravenous BENLYSTA (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN) in Europe. Proteinuria is one of the manifestations of lupus nephritis. BENLYSTA, a BLyS-specific inhibitor, is a human monoclonal antibody that binds to soluble BLyS.

Reasons to Purchase this Report

• Current and future of global Proteinuria Therapeutics market outlook in the developed and emerging markets

• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.

• Regions/countries that are expected to witness the fastest growth rates during the forecast period

• The latest developments, market shares, and strategies that are employed by the major market players

Buy This Complete Business Report With Flat US $2000 Off @ 

Global Proteinuria Therapeutics Market–Taxonomy

By Drug Class:

  • Angiotensin-converting Enzyme (ACE) Inhibitors
  • Angiotensin II Receptor Antagonists (ARBs)
  • Diuretics
  • Others

By Route of Administration:

By Distribution Channels:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa

Global Proteinuria Therapeutics Market – Competitive landscape

Key players engaged in the global proteinuria therapeutics market include GlaxoSmithKline plc, Chinook Therapeutics Inc., Novartis International AG, AbbVie Inc., Calliditas Therapeutics AB, Travere Therapeutics Inc., Walden Biosciences, Ligand Pharmaceuticals Inc., and Retrophin, Inc.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: [email protected]
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Source link


Please enter your comment!
Please enter your name here

Stay in Touch

To follow the best weight loss journeys, success stories and inspirational interviews with the industry's top coaches and specialists. Start changing your life today!


Related Articles